News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Zynerba (ZYNE)’s Failed Cannabidiol Gel Trial Has Upside for Rival GW Pharma (GWPH)



8/8/2017 10:33:03 AM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs
GW Pharmaceuticals (GWPH) popped to a near five-month high Monday after a rival drug from smaller biotech Zynerba Pharmaceuticals (ZYNE) failed in a midstage trial to treat epilepsy.

In early trading on the stock market today, GW Pharma lifted as much as 4.1% to a high last seen in late March. In recent trades, it was up 1.3%, near 119.20. Zynerba, though, plunged 59% to near 6.20.

Read at News Release
Read at Market Watch
Read at News Release


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES